Nucleoside modifications in tRNA anticodons regulate ribosome dynamics during translation elongation and, thereby, fine-tune global protein synthesis rates. The highly conserved eukaryotic Elongator complex conducts specific C5-substitutions in tRNA wobble base uridines. It harbors two copies of each of its six individual subunits, which are all equally important for its activity. Here, we summarize recent developments focusing on the architecture of the Elongator complex, showing an asymmetric subunit arrangement, and its functional implications. In addition, we discuss the role of its proposed active site, its individual subunits and temporarily associated regulatory factors. Finally, we aim to provide mechanistic explanations for the link between mutations in Elongator subunits and the onset of several severe human pathologies.
The capability to produce properly folded and fully functional proteins constitutes one of the hallmarks of all living cells and organisms. De novo protein synthesis has to be spatially and temporally regulated to ensure the production of the correct proteins at the right time and in the right cellular context. In this review, we summarize the latest structural and functional insights on the highly conserved eukaryotic Elongator complex, which initially received its name due to its association with actively transcribing 'elongating' RNA polymerase II [1] . However, it has recently been shown to conduct rather specific chemical modifications on the C5 position of uridine bases in position 34 of eukaryotic tRNAs [2, 3] . Although, tRNA modifications appear to 'only' fine-tune the dynamics of the translation machinery already minor alterations in Elongator activity result in the onset of severe human pathophysiologies, like cancer [4] [5] [6] [7] , neurodegenerative diseases [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , and intellectual disabilities [19, 20] .
Chemical modifications of tRNA bases
Despite their strong sequence variation, all cellular tRNAs need to fold into an almost identical three dimensional (3D) structure to become accommodated in the relatively narrow tRNA-binding sites (A/P/E sites) of the ribosome during translation elongation. The incorporation of specific tRNA modifications affects both, the intrinsic biophysical properties of the modified base and the folding properties of the whole tRNA molecule [21] . Therefore, the possibility of incorporating different modifications vastly expands the range of suitable sequences that can fold into the Abbreviations acetyl-CoA, acetyl-coenzyme A; ASL, anticodon stem loop; Elp, Elongator protein; EM, electron microscopy; FD, familial dysautonomia; KAT, lysine acetyltransferase; Kti, Kluyveromyces lactis toxin insensitive; NMR, nuclear magnetic resonance; SAM, S-adenosyl methionine; TPR, tetratrico-peptide repeat; XL-MS, crosslinking-mass spectrometry.
characteristic L-shaped tRNA structure. Consistently, the gain of tDNA gene copy numbers and isoacceptor tRNAs in higher eukaryotes correlates well with a drastic increase in available tRNA modification enzymes [22] . Today, around 170 unique RNA modifications are described [23, 24] and around 100 of them have been detected in tRNAs of different organisms [25] . Although most of the enzymatic cascades responsible for the modifications have been identified, the detailed chemistry of many of these reactions is still insufficiently described. In detail, substrate selection and recognition are often rather unclear [26] , and the genuine cellular and organismal functions of the resulting modification are also not fully understood [27] . The modifications can roughly be classified into different groups depending on their respective localization within tRNA molecules (i) those located in the acceptor stem regulate the rate and accuracy of aminoacylation (ii) those located in the D-Loop, T-Loop, and variable region ensure folding into the appropriate Lshaped structure and (iii) those located in the anticodon stem loop (ASL) guarantee correct decoding of the respective mRNA codons in the ribosome [21] . In addition to decoding itself, tRNA selection in the ribosomal A-site also constitutes one of the rate-limiting steps during translational elongation. Hence, the use of synonymous codons and tRNA modifications can strongly influence the local elongation speed [28, 29] . As nascent polypeptide chains typically start to cotranslationally fold into their native structures from the N-to C terminus immediately after leaving the ribosomal exit tunnel [30] [31] [32] , ASL modifications also dictate the folding dynamics of newly synthesized proteins by affecting the speed of translating ribosomes during elongation [33] [34] [35] .
Modifications of wobble base uridines
As various wobble base uridine modification pathways have recently been summarized in excellent reviews [36, 37] , here we will focus on the cellular machinery that synthesizes 5-methoxycarbonylmethyl-uridine (mcm 5 U 34 ), 5-methoxycarbonylmethyl-2-thiouridine (mcm 5 s 2 U 34 ), and 5-carbamoylmethyluridine (ncm 5 U 34 ) on uridines in the 34 th position of eukaryotic tRNAs-the eukaryotic Elongator complex [3, [38] [39] [40] . In vitro experiments indicated that these specific base modifications do directly affect binding to the A-site of the ribosome [41, 42] . More precisely, they have been shown to alter the dynamic parameters during the initial selection and proofreading phase of the intermediate codon-anticodon complex [43] . This nicely explains the reduced speed of translating ribosomes on the respective codons, observed in the absence of anticodon modification [44, 45] .
Elongator harbors six individual core subunits and is controlled by four regulatory factors
Around 20 years ago several groups used genome-wide deletion screens in yeast to identify factors that refer resistance to zymocin, a microbial toxin from Kluyveromyces lactis [46] [47] [48] [49] . After confirming that the active c-component of the toxin represents a RNA nuclease that specifically cleaves mcm 5 U 34 and mcm 5 s 2 U 34 modified tRNAs [50, 51] it became apparent that most of the identified resistance factors are involved in the respective tRNA modification cascades. A few years later, it was established that the Elongator complex contains six Elongator proteins (Elp1-6), that arrange in two distinguishable subcomplexes, Elp123 and Elp456, respectively [1, [52] [53] [54] . In addition, four transiently associated proteins, Kti11, Kti12, Kti13, and Kti14 were shown to be involved in the same tRNA modification cascade [38] . In the following paragraphs, we summarize current structural and functional information on the six individual Elongator core subunits and its regulatory factors Kti11, Kti13, and Kti14 (see also Fig. 1 ).
Elongator protein 1 (Elp1)
Elongator protein 1 is the largest Elongator subunit with a mass of approximately 150 kDa. The protein can be subdivided into distinct domains: two sequential WD40 domains in the N terminus (Elp1-NT) and a tetratrico-peptide repeat (TPR) domain in its C terminus (Elp1-CT). Two crystal structures of Elp1 have been determined, the C-terminal portion of human Elp1 (hElp1-CT 715-1332aa ), solved at 3 A resolution (PDB ID 5CQR) (Fig. 1A) and the dimerization domain of yeast Elp1 (Elp1-DD CT 919-1349aa ), solved at a 2.7
A resolution (PDB ID 5CQS) [55] . The hElp1-CT and the yElp1-DD share a similar dimeric structure, despite the low sequence identity between both dimerization domains. The biological relevance of the dimer was further supported in solution using sedimentation analyses and by introduction of specific dimer interface mutations in vitro and in vivo. Moreover, using coimmunoprecipitation experiments, the authors show the importance of Elp1 self-association for the overall assembly of Elongator, both in yeast and humans. In addition, the CT of yElp1 has been predicted to bind to tRNA through a conserved basic region [56] and also holds several phosphorylation sites, involved in the regulation of its tRNA modification activity [57] .
Elongator protein 2 (Elp2)
Elongator protein 2 is the second largest member of the Elongator proteins with a mass of approximately 90 kDa. Two independent and almost identical crystal structures (PDB ID 4XFV and 5M2N) of yeast Elp2 have been solved at 3.2 and 2.8
A resolution, respectively [58, 59] . The protein consists of two similar sized WD40 domains, which are slightly twisted with respect to each other and are stabilized by a so called 'molecular velcro', that connects the first 10 N-terminal amino acid residues of Elp2 with the very C-terminal b-strand of blade 14 in the second WD40 domain. Disrupting this molecular velcro affects the integrity of Elp2 and its binding to Elp1 and Elp3 [58] . Each blade in Elp2 is made up of four b-strands except blade 5 of the first WD40 domain which contains an additional b-strand and three additional a-helices in the second WD40 domain. Phenotypical analyses of Elp2 mutants in yeast targeting conserved loops and other highly conserved surface areas helped to identify regions essential for Elongator function and assembly. Interestingly, mutations in the basic region of Elp2 (loop3 and loop4), originally associated with histone acetylation and microtubule binding, also show phenotypes associated with tRNA modification defects in two recent studies [59, 60] . A similar phenotype was found in two additional regions (aa201-204 and aa552-557), pointing toward their implication in Elongator activity, whereas deletion of loop1 rather seems to affect Elongator assembly.
Elongator protein 3 (Elp3)
The Elp3 subunit is solely responsible for the catalytic tRNA modification activity of Elongator [39] . This component represents the evolutionary most ancient protein of the complex, as almost all archaea, some bacteria and even a few viruses harbor Elp3-like proteins, whereas the other five subunits are missing [39] . The mass of the Elp3 protein is approximately 60 kDa and the sequence conservation among different species is very high (> 40% between bacteria and human). The crystal structure (PDB ID 5L7J) of full-length Dehalococcoides mccartyi Elp3 (DmcElp3) was solved at 2.15
A resolution [61] (Fig. 1A ). This structure showed that DmcElp3 harbors a S-adenosyl methionine (SAM) and a lysine acetyltransferase (KAT) domain, which strongly interact with each other and are additionally connected by a zinc-binding motif. The peptide-binding site in the KAT domain is fully blocked by the SAM domain and the acetyl-coenzyme A (acetyl-CoA)-binding site seems to be occupied by a coordinated loop region. This block may be released upon tRNA binding and thus might explain the stimulation of acetyl-CoA turnover by the presence of tRNA [39] . Deletion of this loop and subsequent crystallization in the presence of acetyl-CoA allowed to determine a second structure at 2. 6 A resolution (PDB ID 5L7L). Although the electron density for acetyl-CoA was too weak to describe its binding mode in detail, this additional structure suggests that the protein does not undergo strong structural rearrangements during the acetyl-CoA binding step. Although DmcElp3 exists as monomer and homodimer in solution, only the latter crystallized. Dimerization involves a 2Fe-2S cluster, which is coordinated by two highly conserved Cys residues from each monomer, and it is additionally stabilized by a conserved network of hydrogen bonds. The tRNA-binding site is located in a central basic pocket between SAM and KAT domains, and footprinting experiments suggested that Elp3 interacts with both the ASL and the D-loop of the tRNA [61] . Finally, the in vitro reconstitution of the modification reaction using recombinant archaeal Elp3 from Methanocaldococcus infernus (MinElp3), tRNA Arg and acetyl-CoA, allowed the authors to propose a reaction scheme [39] . However, this has not been reproduced in a subsequent study, where the same reaction mainly led to unspecific acetylation of surface-exposed lysine residues under identical conditions [61] .
Elongator subcomplex Elp456
The hetero-hexameric Elp456 subcomplex is formed by two copies of Elp4 (50 kDa), Elp5 (35 kDa), and Elp6 (30 kDa) subunits, and has a molecular mass of 230 kDa. Negative staining electron microscopy of the truncated Elp456 subcomplex (Elp4 , Elp5 , and Elp6 ) showed a homogenous sample of ringshaped particles. Subsequently, two highly similar crystal structures (PDB ID 4A8J and 4EJS) of the assembled Elp456 subcomplex were solved at 2.1 and 2. 6 A resolution [54, 62] (Fig. 1A) . The Elp456 heterohexameric ring has dimensions of 105 9 135 A, with monomers of each pair of subunits situated on opposite sides of the ring. The central cavity is 25 9 15 A in dimension and is crossed by two partially disordered loops of Elp5. All three proteins have almost identical conformations with a central, twisted b-sheet flanked by several a-helices similar as observed in RecA-like ATPases except that the RecA b-sheet comprises four strands less. The Elp456 subcomplex specifically binds tRNAs through its most central residues of loop L2 of Elp6 in the central cavity. Elp456 has intrinsic ATPase activity [54, 60] , and in the presence of ATP a strong decrease in the Elp456 affinity for tRNA is observed. This suggested that ATP binding and hydrolysis may regulate tRNA recruitment to or dissociation from the Elongator complex.
Kluyveromyces lactis toxin insensitive 11/13 (Kti11/13) Kluyveromyces lactis toxin insensitive 11 is a relatively small (~9 kDa) and highly conserved protein which belongs to the class of zinc-binding proteins with zinc ribbon fold. Structures (PDB ID 1YOP and 5AX2) of the yeast protein were solved using NMR and crystallography [63] demonstrating that Kti11 can bind either zinc or iron that are both coordinated by the same four highly conserved cysteine residues. Kti11 is involved in the diphtamide biosynthesis and tRNA modification pathways, most likely acting as an electron donor for the [4Fe-4S] clusters of the involved radical S-adenosylmethionine enzymes Dph1, Dph2, and Elp3 [64, 65] . Kti11 has been shown to interact with Elp2 and Elp5 by coimmunoprecipitation experiments [66] and it has been copurified with the Elp123 subcomplex [67] . In addition, binding of Kti11 to Kti13 [68] creates a stable heterodimer [64, 65] that stays associated even in the absence of Elongator [68] .
Kluyveromyces lactis toxin insensitive 13 protein is approximately 35 kDa in mass and the crystal structure (PDB ID 4D4Q) of yeast Kti13 was solved at 2.4
A resolution [65] . The protein adopts a WD40 fold with the typical 'molecular velcro', in which blade 7 is formed by two strands from the N terminus and two strands from the C terminus of the protein. One of the sides of the Kti13 WD40 propeller is characterized by the presence of highly conserved amino acids including several solvent-exposed hydrophobic residues. Although Kti13 is involved in tRNA modification, its deletion does not lead to a complete loss but a decrease in Elongator's modification activity [47] .
Crystal structures of the Kti11/13 heterodimer (PDB IDs 4X33, 4D4O, and 4D4P) solved at 1.45 and 2.9 A resolution, respectively (Fig. 1A) , showed that the conserved surface of Kti13 indeed mediates the interaction with Kti11 [64, 65] . Strikingly, mutations in the interface diminishing the interaction between Kti11 and Kti13 lead to similar phenotypes like the individual deletions in vivo. These observations suggested that their hetero-dimerization is as important for the dipthamine biosynthesis and Elongator-mediated tRNA modification pathways as the activities of the individual proteins [65] .
Kluyveromyces lactis toxin insensitive 14 (Kti14)
Kluyveromyces lactis toxin insensitive 14, also known as Hrr25, belongs to the CK1d family of protein kinases. The 55-kDa protein can be divided into three parts: an N-terminal kinase domain, which comprises almost two-third of the sequence, and two equally sized central and proline/glutamine-rich domains in the C terminus. There are several crystal structures (PDB IDs 4XHH, 4XH0, 4XHG, 4XHL, 5CYZ, and 5CZO) available in the resolution range between 1.8 and 3.0 A, representing proteins from Saccharomyces cerevisiae and Candida glabrata in an apo state (Fig. 1A ) or in complex with ADP, a CK1-7 inhibitor, or the monopolin subunit Mam1 [69] . The conformations of Kti14 and its active site are nearly identical in all obtained intermediates and similar to mammalian CK1d and Schizosaccharomyces pombe CKI1. The kinase domain of Kti14 comprises N-and C lobes and possesses two conserved ion binding sites, S1 and S2. These sites are occupied by either PO 3À 4 , SO 2À 4 or formate ions depending on the crystallization condition used, potentially mimicking the product and priming phosphorylation sites, respectively. The conserved central domain, which interacts with the C-lobe of the kinase domain, comprises a cluster of five short a-helices with one extended loop. Kti14 seems to directly phosphorylate several sites in the CT domain of Elp1, and these phosphorylation events may subsequently regulate Elongator's interaction with Kti12 [57] .
The hexameric Elp456 is asymmetrically attached to a symmetric dimer of Elp123
Early studies showed that purification of endogenous Elongator under different salt conditions yield two defined subcomplexes, namely Elp123 and Elp456 [52, 70] . The architecture of the yeast Elp123 subcomplex and the complete six-subunit Elongator holocomplex was recently unraveled by two independent studies using an integrative approach combining available crystal structures and homology models with EM models and crosslinking mass spectrometry (XL-MS) data [59, 60] . Here, we will summarize how the asymmetric arrangement of the Elongator complex provides the structural framework for understanding its role in tRNA modification. (Fig. 1B) . Even though the previously characterized bacterial Elp3 homolog was present as monomer and dimer in solution [61] , no direct contacts between the Elp3 subunits were observed in the Elp123 subcomplex. The eukaryotic Elongator complex has additional subunits that are completely or at least partially absent in archaea and bacteria, suggesting that Elp3 might not dimerize in eukaryotes. Alternatively, Elp3 dimerization may only occur upon interaction with regulatory factors such as Kti11/Kti13, Kti12, or Kti14 [59] . In yeast, deletion of any of the six Elongator subunits results in the same phenotype, suggesting that all subunits are required for activity [38] . In particular, Elp3 is the catalytically active subunit and performs the tRNA modification in the interface between its KAT and SAM domains [39, 61] . The accessibility of the tRNA-binding pocket in the Elp123 subcomplex, suggests that no conformational change may be needed for the binding of tRNA. Although a stable Elp123 subcomplex can be formed in the absence of Elp456, it is still unknown if the substrate tRNAs can be bound by the Elp123 subcomplex directly, and how the Elp456 is involved in this recruitment step.
Structure of the
Elp123 subcomplex Two copies of the Elp1, Elp2, and Elp3 subunits arrange together to form the symmetric Elp123 subcomplex [59,60]. Negative-stain EM reconstructions of the yeast Elp123 subcomplex show a flattened bilobal structure of 260 A length, 170 A height, and 100 A width. In detail, each lobe is formed by one copy of Elp1, Elp2, and Elp3, and both lobes are linked through dimerization of the Elp1 CT domain [55]. In each lobe, Elp1 forms a scaffold to which Elp2 binds peripherally and Elp3 occupies the central position
Structure of the fully assembled Elongator complex
The Elongator complex is formed by the binding of the Elp456 ring to one of the lobes of the Elp123 subcomplex [59, 60] . The EM structures of Elongator clearly resemble the Elp123 subcomplex in shape and dimensions (270 A length and 180 A height). However, the presence of a hexameric ring density on one of the lobes consequently increases its width (160 A) and determines its asymmetric architecture. In addition, the relative position of the lobes in the Elongator model is different to the one shown in Elp123, as both lobes approach each other to embrace the ring. Using an integrative workflow, the authors could reveal the complete subunit arrangement of the yeast Elongator complex (Fig. 1B) [59, 60] . The Elp456 subcomplex is attached to the CT and NT domains of Elp1, which occupy central positions also validated by antibody EM-labeling. The Elp456 ring sits exactly on top of one of the Elp3 subunits, while the other Elp3 interacts only with Elp1 and Elp2 in the adjacent lobe. The Elp1, Elp456, and Elp3 interactions were confirmed by complementary pull-down experiments using individually purified subunits [59] . Finally, the Elp2 subunits occupy an outer position at both sides of the complex, as supported by EM-labeling and the reconstruction of a partial Elp123 subcomplex [59, 60] . Phenotypical analyses using structure-guided mutants identified several Elp2 loops that are important for Elongator activity and assembly.
Despite their high similarity, there are differences in the independently proposed topological models of the Elongator complex [59, 60] . Firstly, in both studies the NT of Elp1 occupies the bottom part of the complex, while the position of the two Elp1 WD40 domains is slightly shifted. The absence of atomic structures for the two WD40 domains makes the location of individual cross-linked residues rather difficult and uncertain in low-resolution EM maps. Secondly, the orientation of the Elp456 ring in the complex is different. While in Setiaputra et al., the Elp5 subunit binds to the CT of Elp1, in Dauden et al. the Elp4 subunit directly interacts with Elp1-CT. The former study bases its placement on a crosslink between the Elp5 and the Elp1-CT, which is absent in the other study. The alternative ring orientation is defined by common crosslinking data between the Elp4 subunit and both termini of the Elp1 subunit, together with pull-down experiments showing that deletion of the 10 most N-terminal residues of Elp4 is sufficient to disrupt the interaction with the CT of Elp1. Higher resolution structures of the Elp123 subcomplex and the Elongator will help to resolve these discrepancies and clarify if the ring orientation could be dynamic.
As mentioned above, the Elp456 ring is located on top of the Elp3 active site. Based on the decrease in tRNA affinity observed for isolated Elp456 in the presence of ATP, it has been proposed that the Elp456 could be implicated in tRNA delivery to or release from the Elp123 subcomplex [54, 59] . In addition, all the tRNA-binding sites previously described for the individual subunits have been mapped on the Elongator model, revealing a cavity wide enough to accommodate one tRNA molecule. This conserved cavity is formed by the active site of Elp3, the N-terminal WD40 domain of Elp2, the Elp1-CT, and the Elp456 ring, that forms a 30-degree angle with Elp1 ( Fig. 2A) .
The twofold symmetry of the Elp123 subcomplex, with an identical Elp3 active site on both lobes, does not account for the polarized interaction of Elp456 with only one of the lobes. It has been speculated that the binding of the Elp456 ring to one lobe might trigger a conformational change that precludes the loading of a second ring on the other side. As both datasets showed only one ring bound to Elp123, it remains unclear if the Elp123 subcomplex can accommodate two Elp456 rings. To further elaborate on this, Yip and colleagues added an excess of recombinant Elp456 to the purified Elongator, and performed densitometry measurements on protein bands and 2D EM analyses. Despite the brighter densities present in both lobes of the class averages, neither a side view average nor an Elongator model with two rings were shown. Therefore, the binding of a second ring to the Elongator cannot be excluded and additional data are needed to clarify if this situation could also happen in vivo and whether it is functionally relevant.
tRNA modification by Elongator: substitution of the C5 position on wobble base uridines tRNA binding and recognition Several domains in different Elongator subunits have been shown to individually recognize and interact with different parts of tRNAs. In detail, one region in the C terminus of Elp1 binds tRNA [56] , Elp3 binds the D-loop and the ASL of tRNAs in its central cavity formed between the radical SAM and KAT domains (Fig. 2B) [61] , and the Elp456 subcomplex specifically binds ASL of tRNA in its central loop region (Fig. 2C) [54] . The newly identified tRNA-binding cavity of the Elongator complex is large enough to accommodate one-, but not two-, folded tRNA molecules. Interestingly, none of the regulatory Kti-proteins have been reported to recognize tRNAs, indicating that they might rather directly interact with the Elongator complex than recruit tRNA. Elp3 and Elp456 seem to interact with the same region around the modifiable wobble base, which suggests that Elp3 and Elp456 from the same lobe bind tRNA in some sequential order during the reaction cycle. In addition, it was shown that the C-terminal region of Elp1, which is responsible for tRNA binding is also heavily phosphorylated [57] and forms a stable homodimer [55] . Therefore, it remains to be shown if tRNA binding, dimerization and (de-)phosphorylation are coupled events and represent a specific substrate recruitment or rejection mechanism. Elp3 has been shown to connect acetyl-CoA hydrolysis [39] and tRNA binding most likely via the blocking loop conserved in Elp3 family members [61] . It is worth mentioning that although Elp1 and Elp456 can discriminate between tRNA, polyU RNA, or ssDNA [54, 56] , no discriminatory mechanisms have been observed in vitro between modifiable and nonmodifiable tRNAs. Interestingly, the fact that Elp3 recognizes not only the ASL but also the D-loop of the tRNA further expands the regions which could confer such specificity. It remains to be shown if Elongator specifically selects modifiable tRNAs at the substrate recruitment stage and if it employs other quality control mechanisms. Additionally, it cannot be excluded that specific recognition could also involve aminoacylation or other preceding tRNA modifications in different positions. stems from SAM [71, 72] . Since then, it has been established that the Elp3 protein harbors a so called radical SAM domain that contains an iron sulfur cluster, necessary to recruit and bind S-adenosylmethionine [61, 73, 74] . In addition, tRNA binding seems to open the acetyl-CoA-binding pocket [61] and stimulate acetyl-CoA hydrolysis in the KAT domain [39] . Moreover, it has been shown that Kti11 can act as an electron donor for the iron sulfur cluster in Elp3 [64] and that Cbr1 is able to reduce Kti11, ensuring its turnover for a new reaction [75] . Using archaeal MinElp3 the initial cm 5 U modification reaction was recapitulated in vitro under anaerobic conditions, which suggests that the reaction indeed requires a functional iron sulfur cluster and a 5 0 -deoxyadenosyl radical intermediate [39] . However, it still needs to be clarified how the modification reaction is possible in archaea, which lack all otherwise essential Elongator subunits and Kti11 homologs [39, 76] .
Conclusions and perspectives tRNA modification or transcriptional elongation (or both)
The link between Elongator and transcription has been increasingly questioned and the cytoplasmic localization [77] of its six subunits [52, 53, 70, [78] [79] [80] [81] does not agree with its role in transcription elongation. The tRNA modification reaction recapitulated in vitro using the catalytic subunit in archaea [39] together with the high-resolution structure of the bacterial counterpart showing the tRNA-binding pocket [61] further confirmed its role in tRNA modification. It remains to be shown if, besides its role in translational control, Elongator conducts additional biochemical activities in certain organisms, cell types, or cellular compartments, as several reports indicate additional functions of the complex in the plant kingdom [82, 83] .
Elongator modifications as guardians of the proteome
Due to its role as a global translational regulator, the involvement of the Elongator complex in a plethora of different cellular mechanisms and functions remains undisputed. Nevertheless, the potential consequences of the 'braked' translating ribosomes in cells lacking wobble uridine base modifications are still not fully understood and various mechanistic models are currently discussed in the field. The first so called codondependent translational control mechanism was based on the observation that in S. pombe strains lacking Elongator activity, hundreds of proteins are mistranslated, due to their enrichment in affected codons [84] [85] [86] . Other studies supported the idea of a more general stress response that is triggered by the lack of modifications [87] . An elegant study by the Leidel group correlated the altered translational rates, with changes in the above described cotranslational folding dynamics, and the appearance of protein aggregates in yeast and worm [44] . This model may explain how increased cellular tRNA levels, after overexpression of hypomodified tRNA species, could compensate for the lower Asite affinities and rescue Elongator-associated phenotypes in vivo [88] . Nevertheless, it is worth mentioning that aggregates observed in depleted cells do not show an enrichment for proteins with a certain codon bias, and further studies are needed to clarify the detailed molecular mechanisms and to exclude other possible explanations. In summary, specific tRNA modification pathways together with codon bias, concentrations of tRNA isoacceptors, and the level and activity of elongation factors, are highly conserved determinants for the maintenance and fine-tuning of proteome homeostasis.
Elongator mutations related to human diseases
The emerging role of tRNA modification pathways in human diseases, and more specifically Elongator in neurodegenerative diseases, has recently been subject of excellent reviews [89] [90] [91] [92] . The recently resolved overall topology of the Elongator complex [59, 60] and the available crystal structures of individual subunits allow us to localize all currently described patientderived mutations (Fig. 3) . Although we have to take into account that current structural models are low resolution, thus reflecting the overall architecture, they will hopefully facilitate the analyses of mechanistic and structural consequences of the identified mutations in patients. In detail, the CT of Elp1 is missing in a subpopulation of familial dysautonomia (FD) patients, due to a mutation (IVS20 + 6T) that leads to splicing defect and results in the expression of a substantially C-terminally truncated Elp1 [10] . As Elp1 acts as a scaffold in both the Elp123 and the Elongator structures and its CT domain mediates dimerization, the presence of a truncated form of Elp1 may prevent assembly of the complexes and diminished its tRNA modification activity. The mechanistic consequences of other disease-related point mutations in Elp1 linked to FD and bronchial asthma (R696P, P914L, C1072S, and P1158L) still need to be established. Mutations in Elp2 associated with intellectual disabilities (H206R, R462W, and T555P) are located on the conserved inner side of the subunit, in close proximity to the active site of Elp3, and may mediate the interaction with the other subunits. It remains to be shown if these Elp2 mutations, and the E795G mutation related to cardiac hypertrophy, affect the integrity of the complex or directly influence the activity of Elp3. A variety of mutations in Elp3 have been described in Fig. 3 . Disease relevance of Elongator-mediated tRNA modification. The Elongator topological model is shown in gray and the diseaserelated mutations are highlighted in the corresponding subunit color (orange for Elp1, yellow for Elp2, pink/magenta for Elp3, and green for Elp4). The spheres represent the described mutations, while for Elp1 and Elp4 the entirely affected part/subunits are colored. The Elongator model is shown in two different orientations. The diseases associated with the affected subunits are stated together with their corresponding mutations.
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FEBS Letters 592 (2018) 502-515 ª 2017 Federation of European Biochemical Societies amyotrophic lateral sclerosis patients [18] , cancer genomics databases (R404T, R424K, D443N) [7, 61] and model organisms (R456K and R475K) [17, 93] . Nevertheless, despite clear indications of its involvement in development and maintenance of the central nervous system, no direct correlation between human diseases and specific mutations could yet be established. The embryonic lethality of Elp1 and Elp3 knock-out mice [12, 94] , suggests that mutations in the catalytic subunit in humans might lead to imminent death, rather than triggering the onset of a severe disease. In addition, genomic variants in Elp4 have been associated with the appearance of centro-temporal spikes in Roland epilepsy [11] , although these results could not be validated using a different cohort of patients [95] . Mutations in the promoter region of human Kti11-homolog (Dph3) have recently been involved in skin cancer [96] and skin lesions [97] . In addition, a potential human homolog of Kti13 (DelGEF), has been implicated in the onset of hereditary deafness [98] . Nevertheless, it is worth mentioning that these regulatory factors also participate in other cellular pathways than Elongator-mediated tRNA modification, which might also be causative for these disease phenotypes.
In general, it remains a mystery how specific mutations in different Elongator subunits cause such a variety of distinct neurodegenerative diseases. If all described diseases would result from mutations that simply diminish or reduce the tRNA modification activity of the Elongator [9] , a similar disease profile could be expected. We will need to understand if different Elongator subunits and regulatory factors are targets of specific signaling cascades and show cell type specific functions in multicellular organisms (e.g., different neuronal subtypes within the central nervous system). Indeed, recent studies have highlighted the specific involvement of Elongator in the differentiation and migration of only a subset of projection neurons [99, 100] .
In summary, the availability of novel structural information together with increasing clinical evidences on its key role in neurodegenerative diseases make the Elongator complex itself and its regulatory pathways a prime target for the future development of diagnostic and therapeutic tools. 
